Printed from Voxsanity (voxsanity.com.au) — NCT06660394 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
The person has been diagnosed with Dravet Syndrome (DS), with seizures that first started between 1 and 20 months of age.
The person has a history of at least one of these seizure types: prolonged generalized tonic-clonic, hemiclonic, myoclonic, tonic, atonic, atypical absence, focal impaired awareness, or nonconvulsive status epilepticus.
The person is currently experiencing at least one of these specific motor seizure types: generalized tonic-clonic, bilateral tonic, bilateral clonic, bilateral atonic affecting the trunk or legs, focal motor (including hemiclonic), or focal seizures that spread to become tonic-clonic.
The person has had an average of at least 4 of these motor seizures per month over the 3 months before screening.
The person has been taking between 1 and 4 anti-seizure medications at a stable dose for at least 4 weeks before screening.
The person, their parent, or their caregiver is willing and able to complete seizure diaries throughout the study, as assessed by the investigator.
The person (or their parent or guardian) is willing and able to provide written informed consent.
Who may not be able to join:
The person has a history of infantile or epileptic spasms.
The person was admitted to a medical facility for a severe seizure episode (status epilepticus) requiring breathing machine support within the 3 months before screening.
The person has a progressive brain or nervous system disorder identified through brain imaging or genetic testing.
The person has a brain injury or lesion unrelated to their primary condition that could be causing seizures.
The person is taking certain medications that are not permitted in this trial (confirm with trial site for the specific list).
The person is currently using any cannabis product or cannabidiol that is not in oral solution, capsule, or tablet form, was not obtained from a government-approved source, or contains 50% or more THC.
The person has another serious or unstable medical condition — such as certain heart, lung, liver, kidney, neurological, psychiatric, or other significant health problems — that could affect their ability to participate or influence the study results.
The person is unwilling to follow the study requirements or timelines.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Prince of Wales Hospital, Randwick, New South Wales
Sydney Children's Hospital, Randwick, New South Wales
Children's Hospital at Westmead, Westmead, New South Wales
Royal Brisbane & Women's Hospital, Herston, Queensland
Queensland Children's Hospital, South Brisbane, Queensland
Austin Hospital, Heidelberg, Victoria
Royal Children's Hospital Melbourne, Parkville, Victoria
The Alfred Hospital, Melbourne,
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06660394
Sponsor: Longboard Pharmaceuticals
Phase: Phase 3
Status: Recruiting
Condition: Epilepsy
Trial contact: +45 36301311
More information: https://clinicaltrials.gov/study/NCT06660394
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
The person has been diagnosed with Dravet Syndrome (DS), with seizures that first started between 1 and 20 months of age.
The person has a history of at least one of these seizure types: prolonged generalized tonic-clonic, hemiclonic, myoclonic, tonic, atonic, atypical absence, focal impaired awareness, or nonconvulsive status epilepticus.
The person is currently experiencing at least one of these specific motor seizure types: generalized tonic-clonic, bilateral tonic, bilateral clonic, bilateral atonic affecting the trunk or legs, focal motor (including hemiclonic), or focal seizures that spread to become tonic-clonic.
The person has had an average of at least 4 of these motor seizures per month over the 3 months before screening.
The person has been taking between 1 and 4 anti-seizure medications at a stable dose for at least 4 weeks before screening.
The person, their parent, or their caregiver is willing and able to complete seizure diaries throughout the study, as assessed by the investigator.
The person (or their parent or guardian) is willing and able to provide written informed consent.
Who may not be able to join:
The person has a history of infantile or epileptic spasms.
The person was admitted to a medical facility for a severe seizure episode (status epilepticus) requiring breathing machine support within the 3 months before screening.
The person has a progressive brain or nervous system disorder identified through brain imaging or genetic testing.
The person has a brain injury or lesion unrelated to their primary condition that could be causing seizures.
The person is taking certain medications that are not permitted in this trial (confirm with trial site for the specific list).
The person is currently using any cannabis product or cannabidiol that is not in oral solution, capsule, or tablet form, was not obtained from a government-approved source, or contains 50% or more THC.
The person has another serious or unstable medical condition — such as certain heart, lung, liver, kidney, neurological, psychiatric, or other significant health problems — that could affect their ability to participate or influence the study results.
The person is unwilling to follow the study requirements or timelines.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Longboard Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
25 September 2024
Est. completion
21 August 2026
Where this trial is recruiting
🇦🇺 Australia
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇳 China
🇫🇷 France
🇩🇪 Germany
🇮🇹 Italy
🇯🇵 Japan
🇱🇻 Latvia
🇲🇽 Mexico
🇵🇹 Portugal
🇷🇸 Serbia
🇪🇸 Spain
🇬🇧 United Kingdom
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Frequency Percent Change in Countable Motor Seizures During Treatment Compared to Baseline
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.